Pale Fire Capital SE’s Larimar Therapeutics LRMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-43,000
Closed -$131K – 68
2026
Q2
$131K Buy
+43,000
New +$171K 0.01% 68
2026
Q1
– Sell
-45,218
Closed -$172K – 70
2025
Q4
$172K Hold
45,218
– – 0.01% 54
2025
Q3
$146K Buy
45,218
+7,700
+21% +$28.9K 0.02% 48
2025
Q2
$108K Hold
37,518
– – 0.01% 56
2025
Q1
$80.7K Buy
37,518
+5,209
+16% +$16.5K 0.01% 51
2024
Q4
$125K Hold
32,309
– – 0.03% 40
2024
Q3
$212K Buy
32,309
+18,017
+126% +$145K 0.03% 41
2024
Q2
$104K Buy
+14,292
New +$109K 0.01% 37
2024
Q1
– Sell
-12,040
Closed -$54.8K – 70
2023
Q4
$54.8K Hold
12,040
– – 0.01% 70
2023
Q3
$47.6K Buy
+12,040
New +$45.5K ﹤0.01% 68

Other funds holding LRMR

Pale Fire Capital SE's LRMR Position: Q3 2026 in Review

Pale Fire Capital SE sold out of Larimar Therapeutics (LRMR) in Q3 2026, closing a stake of 43,000 shares — an estimated $131K sold.

Pale Fire Capital SE first reported a position in LRMR in Q3 2023 and held it in 10 quarters. The position peaked at $212K in Q3 2024. 145 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Pale Fire Capital SE reported no remaining Larimar Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Pale Fire Capital SE sold 43,000 Larimar Therapeutics shares in Q3 2026, an estimated $131K.
  • Pale Fire Capital SE first reported a position in Larimar Therapeutics in Q3 2023 and held it in 10 quarters.
  • Pale Fire Capital SE's Larimar Therapeutics position peaked at $212K in Q3 2024.
  • 145 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Pale Fire Capital SE's 13F filing for Q3 2026, filed 13 Nov 2026.